Aveanna Healthcare (AVAH) Q3 2024 earnings summary

Executive summary

• Q3 2024 revenue reached $509 million, up 6.5% year-over-year, with growth across all segments, especially Medical Solutions and Private Duty Services.

• Adjusted EBITDA rose 32.2% to $47.8 million, driven by improved payer rates and cost reductions.

• Net loss narrowed to $42.8 million from $102.4 million in Q3 2023, with operating income rebounding to $34 million.

• Strategic focus on preferred payer agreements, legislative rate increases, and government partnerships is accelerating growth and hiring, especially in Private Duty Services.

• Enhanced 2024 outlook: full-year revenue expected at ~$2 billion and Adjusted EBITDA above $168 million.

Financial highlights

• Q3 consolidated gross margin was $159.7 million (31.4%), up from 30.8% in Q3 2023.

• Free cash flow for Q3 was strong, with year-to-date operating cash flow at $19.2 million and free cash flow at $17 million.

• Liquidity at quarter-end was $285 million, including $79 million cash and undrawn revolver; incremental borrowing capacity was $37.9 million under the securitization facility.

• No material term loan maturities until July 2028; most variable rate debt is hedged with $520 million in swaps and $880 million in caps.

• Net loss for nine months was $40.1 million, improved from $108.8 million loss in 2023.

Outlook and guidance

• 2024 revenue guidance is ~$2 billion; Adjusted EBITDA expected to exceed $168 million, both raised from prior guidance.

• Positive momentum in rate increases and preferred payer agreements expected to continue into 2025.

• Q4 margins expected to normalize after a strong Q3, with continued growth into 2025.

• Sufficient liquidity is anticipated for at least the next twelve months.